Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HSP90 as a Predictive Marker of the Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Peritoneal Carcinomatosis From Ovarian Origin.

NCT02803515 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Nice as lead sponsor.

NCT NCT02803515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02803515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HSP90 as a Predictive Marker of the Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Peritoneal Carcinomatosis From Ovarian Origin.
Lead sponsor
Centre Hospitalier Universitaire de Nice
Phase
Not applicable
Overall status
Terminated
Start date
January 16, 2017
Completion date
July 2, 2017
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peritoneal carcinomatosis